scroll_to_top_v1__1_.svg
result
Science in Service
of
Medicine
result
President's letter
2022 Metrics
Cycle of Translation
From Discovery to Clinic
Down_arrow.svg
Up_arrow.svg
Close_menu.svg
House.svg
Small_Arrow.svg
Small_Arrow.svg
Discovery to Clinic
Clinical Research
Small_Arrow.svg
Houston Methodist joins the Gulf Coast Consortia
Houston Methodist Joins the Gulf Coast Consortia
Share this story
Facebook.svg
Twitter.svg
Linkedin.svg
The Houston Methodist Research Institute has joined the Gulf Coast Consortia. The GCC is a Houston-Galveston-based organization that is one of the largest inter-institutional academic cooperatives in the nation focused on building strong, collaborative, biomedical research groups and interdisciplinary training opportunities for PhD students and postdoctoral fellows. Baylor College of Medicine, Rice University, University of Houston, The University of Texas Health Science Center at Houston, The University of Texas Medical Branch at Galveston, The University of Texas MD Anderson Cancer Center and the Texas A&M University Institute of Biosciences and Technology also are members. The core strength of the Houston Methodist research tradition lies in its collaborative, translational commitment and focus on solving clinician-driven challenges. This driving force is kindred to the GCC’s mission to integrate its member institutions' strengths to build an interdisciplinary, collaborative research infrastructure and training environment that surpasses the capability of any single institution. The Houston Methodist Research Institute was always intended to be collaborative rather than competitive to focus exclusively on multi-disciplinary, translational research at the intersection of fields. Designed to form the bridge between traditional disciplines to develop treatments with ready applicability to human disease, the Research Institute uses its physical connection to the hospital and technological expertise in FDA approval pathways to streamline the process of translating laboratory research into treatments and cures for patients. Taking the approach of bridging disciplines with clinical needs and developing new technologies, the Research Institute focuses on shepherding innovations through preclinical and clinical development, clinical trials, FDA approval and commercialization. It is not degree granting, rather, it partners with programs seeking a translational or clinical perspective to its educational curriculum. The Research Institute training programs follow a traditional path — from graduate programs in clinical translation to professional level training in skills acquisition, advanced technology and biomedical research. Houston Methodist’s learners and leaders come from premier institutions around the world. The Research Institute’s strengths in cancer, regenerative medicine, infectious disease, neuroscience and translational imaging technologies fit well with GCC’s existing and anticipated scientific endeavors, said Kathleen Matthews, Ph.D., a founder and chair emeritus of the GCC and Stewart Memorial Professor of Biochemistry and Cell Biology Emerita, Rice University. “We are delighted that the Houston Methodist Research Institute has become the eighth member of the GCC, and we look forward to further engaging its faculty, researchers, postdoctoral fellows and staff in the many GCC research and training enterprises,” Matthews said. “Over the years, the Research Institute has greatly valued our collaborations with institutions that are members of the GCC,” said Edward A. Jones, President and CEO of the Houston Methodist Research Institute. “Research synergies among GCC institutions create a culture of creativity that opens new opportunities for discoveries that positively impact human health. Membership in the GCC now provides a wonderful opportunity to add our many strengths to the consortium, including world-class research in cancer, heart and cardiovascular medicine, immunobiology, and nanomedicine, and more than twenty core facilities that provide our investigators and external researchers access to exceptional scientific technology.”
Share this story
Facebook.svgTwitter.svgLinkedin.svg